Thirty adult patients who received intravenous colistin (5.1 ؎ 2.4 mg/kg/day) were reviewed to evaluate dosing with respect to nephrotoxicity, which occurred in 10 (33%) patients within the first 5 days of treatment. Excessive colistin dosing was frequent (47%), often (71%) resulted from the use of actual body weight in obese patients, and was associated with higher rates of nephrotoxicity (80% versus 30%, P ‫؍‬ 0.019).
45.5 ϩ 2.3 ϫ (height in inches exceeding 5 feet) for women (2) . Patients were considered obese if the ABW was greater than 140% of the IBW. Classification of each dosing regimen was based on a modification of the package insert as described by Evans et al. (3) , in which dosing recommendations are based on creatinine clearance (CrCl) estimates (1) . A daily dose was considered excessive, normal, or low-normal if it was greater than, within, or below Ϯ0.4 mg/kg/day, respectively, of the recommended dosing range using IBW.
Nephrotoxicity was defined as at least two consecutive S CR measurements with an increase of 0.5 mg/dl from baseline at least 24 h apart after two or more days of colistin therapy. The RIFLE criteria were used to evaluate the severity of acute kidney injury (9) .
All statistical analyses were performed using SPSS version 14.0 for Windows (Chicago, IL). Continuous variables were analyzed using either the t test or the Mann-Whitney U test; categorical data were compared using either the 2 or Fisher's exact test when appropriate.
Thirty patients were prescribed colistin for treatment of multidrug-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae isolated primarily from respiratory (63%) or urine (20%) sources. The mean cumulative intravenous colistin dose was 2,559 Ϯ 2,088 mg and was administered for a median of 8 (range, 3 to 24) days. Dosing of colistin based on ABW and IBW was 3.9 Ϯ 1.2 and 5.1 Ϯ 2.4 mg/kg/day, respectively. Subsequent analysis of dosing is listed in Table 1 . Fourteen patients (47%) received an excessive colistin dose. In 10 of these cases (71%), the dose was calculated based on ABW, instead of IBW, in obese patients. Eleven patients (37%) received low-normal doses (Table 1) .
Ten patients (33%) developed nephrotoxicity during colistin treatment; all had baseline S CR values Յ1.4 mg/dl, received greater than 4 mg/kg/day, and developed renal impairment within the first 5 days of treatment. The median S CR at the beginning and end of therapy was 1.0 and 2.5 mg/dl, respectively. Based on RIFLE criteria, 3, 5, and 2 patients met the criteria for injury, failure, and end-stage kidney disease, respectively. Table 2 lists a comparison of patient characteristics based on development of nephrotoxicity. Patients who developed nephrotoxicity were older, had a higher baseline APACHE II score, and were more likely to have been treated in an intensive care unit (ICU); however, only age was statistically significant. No differences in treatment duration or cumulative dose of colistin were observed; however, patients administered excessive daily colistin doses were significantly more likely to develop nephrotoxicity than those who received normal or low-normal doses (P ϭ 0.019). Patients who received excessive doses because ABW was used for dose calculation in the obese were 13.2 times more likely to develop nephrotoxicity (95% confidence interval, 2.1, 82.1) than patients who received normal or lownormal doses (P ϭ 0.005). Alternative explanations for developing nephrotoxicity that were statistically significant included receipt of concomitant diuretics and/or vasopressors. All four patients receiving vasopressors in this study developed nephrotoxicity; the remaining six patients who developed nephrotoxicity all received excessive daily colistin doses.
The major findings of this study were the 33% nephrotoxicity rate among hospitalized patients who received colistin, the statistically significant association between development of nephrotoxicity and excessive colistin dosing, and the observation that excessive colistin doses were usually administered because ABW rather than IBW was used to calculate the daily mg/kg dose. For example, in one 166-kg patient with a CrCl Ͼ120 ml/min at baseline, a 5.1-mg/kg/day dose based on ABW was given. Based on IBW, however, the dose given was 14.3 mg/kg/day. The patient developed nephrotoxicity on day 2 of therapy. Although the IBW is recommended in the package insert, data validating this recommendation do not exist and it is unclear which weight measure is most appropriate. Alternative reasons other than colistin dosing that could have explained development of nephrotoxicity were older age, receipt of diuretics, and receipt of vasopressors. After patients who received vasopressors were excluded from the analysis, nephrotoxicity was observed only in patients who received excessive daily dosing. Due to the small number of patients remaining (n ϭ 26), a multivariate logistic regression model could not be performed. The 33% rate of nephrotoxicity observed is similar to a report by Levin et al. (11) but higher than those found in other contemporary studies (4) (5) (6) (7) 15) . The majority of these studies used less than 3 mg/kg/day of CBA (4-7). The higher dosing of 5.5 mg/kg/day in patients who developed nephrotoxicity in this cohort may account for the differences among studies. Wallace et al. found a higher incidence of renal lesions in rats receiving once-daily administration of a clinically relevant colistin dose compared to a twice-daily regimen (19) . Since all patients were dosed multiple times daily in this cohort, this relationship could not be evaluated. Additionally, a study by Hartzell et al. (8) found that patients treated with colistin for greater than 14 days were 3.7 times more likely to develop nephrotoxicity. Since all patients developed nephrotoxicity by day 5 of therapy, this relationship could not be evaluated.
Contemporary, reliable colistin pharmacokinetic (PK) data show a much lower concentration-time profile than previously described (12, 14, 16, 18) . For example, a report by Plachouras et al. (18) shows sub-MIC colistin concentrations during the first few days of therapy in critically ill patients. These PK data suggest that increased daily doses are warranted; however, the data from this analysis suggest that administration of any daily colistin dose greater than that currently recommended (i.e., 2.5 to 5 mg/kg/day) be done cautiously, as this may increase nephrotoxicity risk.
In conclusion, excessive daily colistin dosing led to the more frequent development of nephrotoxicity and was often due to the use of the ABW for dose calculation in obese patients. These data suggest that using a measure of lean body mass, such as IBW, to dose colistin may be less nephrotoxic. Close monitoring of renal function, specifically during the first 5 days of therapy, may identify patients in whom renal toxicity of colistin is likely to occur. Further investigation must continue to identify the optimal colistin dose from both efficacy and toxicity perspectives.
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